Nuvalent Launches with $50M Series A Financing from Deerfield Management to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3t6e91A
via IFTTT